Archer will develop and pursue regulatory approval for a companion diagnostic that will help find patients who may benefit from one of Merck's drug candidates.
Merck will use Definiens' web-based collaboration software platform alongside Definiens' image-analysis technologies for biomarker quantification.
The German drugmaker plans to advance the NSCLC treatment in parallel with tissue-based and liquid biopsy companion assays that can identify best responders.
The reagents involved in the deal improve the specificity and fidelity of PCR reactions.
The two companies have signed a new master collaboration agreement under which HTG will develop custom assays for use in earlier stages of Merck's drug development process.
The tests were developed as part of a partnership with Merck KGaA, one of the manufacturers of the anti-EGFR therapy Erbitux.
Guardant is providing its Guardant 360 CDx test for a clinical trial of Merck's small molecule, c-Met kinase inhibitor called tepotinib.
The companies are aiming to identify treatment-response biomarker signatures in patients with advanced melanoma.
The company said its proxy-CRISPR tool can facilitate precise gene editing and eliminates the need for genetic engineering of naturally occurring CRISPR proteins.
The moves underscore a growing belief in industry and academia that the cell-derived vesicles could be the biomarker of choice for next-generation tests and therapies.
The US National Institutes of Health's All of Us project awarded $4.6 million to the company Color to develop a genetic counseling resource for the program.
The Times of India reports on a pilot study that used genomic testing to determine whether patients had drug-resistant tuberculosis.
New guidelines say that more women may benefit from genetic testing for hereditary breast or ovarian cancer, according to the Los Angeles Times.
In Cell this week: small proteins identified among human microbiome, role for tumor microbes in pancreatic cancer survival, and more.